470

Compound name
Selpercatinib
Alt Name
LOXO-292
Retevmo
Compound Image
Selpercatinib.png
SMILES
CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
MW
525.60
Brutto
C29H31N7O3
InChI
InChI=1S/C29H31N7O3/c1-29(2,37)18-39-24-9-25(28-21(10-30)13-33-36(28)17-24)20-5-6-26(31-12-20)34-15-22-8-23(16-34)35(22)14-19-4-7-27(38-3)32-11-19/h4-7,9,11-13,17,22-23,37H,8,14-16,18H2,1-3H3
InChI Key
XIIOFHFUYBLOLW-UHFFFAOYSA-N
Approval Jurisdiction
2020 FDA
Approved for clinical use
NSCLC, MTC, Thyroid Cancers
CAS
2152628-33-4
PubChem CID
134436906
Action
RET fusions
Approved Drug List
1
Commercial Vendor
Eli Lilly